Replies to post #157097 on Biotech Values

[caravon]

Maybe they'll get lucky

With their business model (to piggyback Tiva with existing combos), they indeed need a lot of luck.

By the time ARQL completes Ph2&3 trials with the existing Standard of Care combo in 4-7 years, there are new treatment paradigms.